Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Leap Therapeutics Inc (LPTX)

Leap Therapeutics Inc (LPTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,866
  • Shares Outstanding, K 22,949
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • 60-Month Beta 2.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.40
  • Number of Estimates 1
  • High Estimate -0.40
  • Low Estimate -0.40
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.35 +21.48%
on 06/10/19
1.74 -5.75%
on 06/21/19
+0.12 (+7.54%)
since 05/24/19
3-Month
1.35 +21.48%
on 06/10/19
2.17 -24.42%
on 04/02/19
-0.26 (-13.68%)
since 03/26/19
52-Week
1.35 +21.48%
on 06/10/19
9.28 -82.33%
on 06/29/18
-7.49 (-82.04%)
since 06/26/18

Most Recent Stories

More News
Leap Therapeutics Reports First Quarter 2019 Financial Results

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2019.

LPTX : 1.64 (-0.61%)
Factors of Influence in 2019, Key Indicators and Opportunity within IDEXX Laboratories, Aegion, NetScout, Castlight Health, inc, Leap Therapeutics, and Speedway Motorsports -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IDEXX Laboratories, Inc....

NTCT : 24.44 (-0.04%)
AEGN : 17.28 (+1.65%)
CSLT : 2.95 (-1.67%)
IDXX : 269.89 (-0.52%)
LPTX : 1.64 (-0.61%)
TRK : 18.31 (-1.88%)
Potential Blockbuster Gene Therapy Programs to Watch in 2019

Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable.

SGMO : 9.61 (-1.23%)
QURE : 74.64 (-0.48%)
BLUE : 119.66 (-0.22%)
LPTX : 1.64 (-0.61%)
GNPX : 1.22 (+1.25%)
Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President...

LPTX : 1.64 (-0.61%)
Leap Therapeutics Reports Clinical Update and 2018 Financial Results

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported an update on its clinical development programs along with financial...

LPTX : 1.64 (-0.61%)
Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer

Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society...

LPTX : 1.64 (-0.61%)
Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting at the Society of Gynecologic...

LPTX : 1.64 (-0.61%)
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an underwritten public offering of 6,571,428...

LPTX : 1.64 (-0.61%)
Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 6,571,428...

LPTX : 1.64 (-0.61%)
Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Match Group, Inc. (NASDAQ:MTCH),...

AR : 5.48 (+1.48%)
BPMX : 0.72 (-9.23%)
MTCH : 66.66 (-0.67%)
GRC : 31.25 (unch)
LPTX : 1.64 (-0.61%)
BYD : 26.84 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade LPTX with:

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

2nd Resistance Point 1.71
1st Resistance Point 1.68
Last Price 1.64
1st Support Level 1.62
2nd Support Level 1.59

See More

52-Week High 9.28
Fibonacci 61.8% 6.25
Fibonacci 50% 5.32
Fibonacci 38.2% 4.38
Last Price 1.64
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar